(228) Programming antitumor gamma delta T cells via a phosphoantigen nanoparticle delivery vehicle
Introduction: Vγ9Vδ2 T cells are a subset of γδ T cells that can efficiently eradicate tumors [1]. Adoptive Vγ9Vδ2 cell therapies exist clinically but require costly and slow on-site cell isolation and expansion [2,3]. Activating Vγ9Vδ2 T cells in situ would overcome these issues, but delivery challenges of activation agents have stymied clinical development. We present a self-assembling nanoparticle (NP) engineered to activate Vγ9Vδ2 T cells in situ composed of a hydrophilic, tumor-targeting block and a hydrophobic polymer block containing Vγ9Vδ2-activating phosphoantigen (pAg) prodrug monomers (pAgMAs).
Learning Objectives:
define Vγ9Vδ2 T cell & describe potential as a cancer immunotherapy.
list examples of Vγ9Vδ2 T cell-based therapies and describe their strengths and weaknesses.
describe a potential therapy to harness Vγ9Vδ2 T cells in vivo.
